In endometrial cancer [37], colorectal cancer [38], and various solid tumors [39], a high correlation between TP53 mutations and p53 immunohistochemistry (IHC) has been established (concordance rate > 90%), making p53 IHC a reliable surrogate marker for TP53 status. Here, TP53 is linked to endometrial cancer.